Fresh off of a European approval for a subcutaneous version of Saphnelo, AstraZeneca is doubling down on the benefits of the ...

Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...

M+C Saatchi North America is turning to a longtime pharma pro to serve as its inaugural medical advisor. | M+C Saatchi North ...

Forget about Herceptin. There’s a new HER2 agent that ought to be used in HER2-positive stomach cancer, and that’s Jazz ...

Chief among the factors driving a sense of optimism among the biopharma leaders was the unfreezing of the biotech investing ...

Shortly after scoring a historic FDA nod for its Wegovy pill, Novo Nordisk is off to the races with the oral obesity med’s ...

The U.S. previously recommended more childhood vaccines than any peer nation, according to the HHS, which pointed out that ...

After shepherding the company through its first approval and the successful launch of blockbuster autoimmune drug Vyvgart, ...

A positive top-line readout from a phase 3 trial has emboldened Incyte to seek the FDA’s blessing for the company’s Monjuvi ...

Daiichi Sankyo plans to splash out some 300 billion yen ($1.9 billion) on Enhertu manufacturing facilities across the globe, ...

Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2026. | In this tracker, Fierce Pharma is recording the ...